Instil Bio, Inc.
A Dallas biotech firm working on a personal kind of cancer immunotherapy: it takes a patient's own immune cells that have already wandered into a tumor, multiplies them into an army in the lab, and infuses them back to hunt down the cancer. Founded in 2018, the company also developed a CoStAR platform meant to give those engineered cells an extra "on" switch when they meet a tumor. Its name plays on "instil" — boosting the body's own natural immune response to fight disease.
Granted 30.0K · Sold 30.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| McGaughy R Kent JrDirector · 1 transaction | — | 16.25Mas of Mar 2022 | — | — | — |
| Laumas SandeepCFO and CBO · 4 transactions | — | 12.5K | 30.0K | — | 30.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -30.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.